Biomining Battery Metals: Promising Science, Pre-Commercial Reality

#

The bacteria that have pulled copper and gold from rock for decades are now being pointed at a much harder target: the lithium, cobalt, and nickel that power electric vehicle batteries. It is tempting to assume the transfer is straightforward. It is not.

Battery manufacturers and automakers face mounting pressure to secure mineral supplies that satisfy Environmental, Social, and Governance (ESG) criteria while sidestepping the geopolitical concentration of metals like cobalt. That pressure has drawn fresh attention to biomining critical minerals, the use of microorganisms to mobilise metals from ore and waste.

Here is the framework you need to evaluate the ventures now raising capital in this space. This analysis separates the proven science from the laboratory optimism, weighs the scaling barriers that keep the technology pre-commercial, and positions biological extraction against faster-moving alternatives competing for the same battery supply chains.

Beyond base metals: mapping the microbial shift to battery supply chains

Copper and gold bioleaching have run at commercial scale for decades. That maturity is precisely what makes the current moment misleading, because the microbial toolkit for base metals does not transfer cleanly to battery chemistry.

The foundational mechanism connecting copper’s commercial success to battery metal aspirations is bioleaching technology, which has matured through decades of industrial deployment in copper and gold but now faces a genuinely different set of mineralogical and chemical challenges as it pivots toward lithium-ion battery feedstocks.

Biological extraction of lithium, cobalt, and nickel sits at a different point entirely. It is progressing through laboratory studies and early pilot efforts, and it remains pre-commercial. It will not materially ease near-term battery supply constraints.

What has changed is the money. Institutional research and venture capital surged into this sub-sector across 2025 and 2026, targeting the technology readiness gap directly.

A 2026 report from Forbion, titled “How biology is reshaping the mining industry,” catalogued active venture-financed startups spanning phytomining, using plants to draw nickel and rare earths from soil, and microbial recycling firms recovering lithium, cobalt, and nickel from e-waste. The report highlighted at least one $45 million Series A round in 2025 led by the Forbion BioEconomy fund.

Crucially, this pipeline is aimed at secondary feedstocks, not virgin ore. That distinction matters for where the value sits.

Endolith is a clear example. A May 2025 report in Metal Tech News noted the biotech startup, which uses proprietary microbes to biomine copper and lithium from overlooked low-grade sources such as second-rate ores, geothermal brines, and bauxite tailings, is actively expanding pilot projects into cobalt, nickel, vanadium, and zinc.

The institutional backing runs deeper than startups. The US government-linked NLR Critical Minerals program and Australia’s CSIRO, which established foundational lab-scale battery extraction work in 2021, are both advancing the science.

For you, the read is simple. Allocating capital here today is a venture-stage biology play, not an investment in mining infrastructure. Understanding that distinction is the first defence against misjudging your timelines for a return.

How biological extraction operates on secondary ores and waste

To evaluate any startup’s technical claims, you need to understand what the microbes are actually doing, and why battery metals demand different biological tooling than copper.

The foundational mechanism is bioleaching. Acidophilic bacteria, acid-loving species such as Acidithiobacillus ferrooxidans and Acidithiobacillus thiooxidans, along with fungal species like Aspergillus niger, produce acids and other compounds that mobilise metals from a solid matrix into solution. Once dissolved, the metals can be recovered downstream.

Lithium is the awkward one. Its behaviour inside mineral structures and in solution chemistry differs substantially from base metals, which means the biological challenge is genuinely distinct rather than a matter of tweaking an existing process.

The commercial logic centres on secondary sources: black mass (the shredded residue of spent lithium-ion batteries), mine tailings, and metallurgical processing residues. Targeting these waste streams offers better economics, supports circular economy goals, and avoids the land disturbance of primary extraction.

The laboratory numbers have climbed sharply. A June 2025 review in the Synthetic Biology Journal reported optimised recovery rates of 60-80% for lithium and 85-90% for cobalt and nickel, achieved at 30-40°C and highly acidic conditions of pH 1.5 to 3.0.

Process intensification pushed those figures higher. A July 2026 study in MDPI’s Molecules demonstrated that combining mixed microbial cultures with ascorbic acid raised lithium and cobalt leaching efficiencies to approximately 95% and 94% at high solids loading, up from baselines of 64% and 40%.

Closed-loop systems are advancing too. The University of Edinburgh demonstrated in 2025 a closed-loop biotechnology that recovered nickel, manganese, and copper from relevant waste streams, pairing microbial leaching with downstream recovery.

The takeaway for your due diligence is this: the real value is not replacing primary mining. It is economically unlocking low-grade waste streams that conventional chemical methods leave stranded. When a startup pitches high recovery rates, ask whether those rates hold on messy, real-world feedstock.

The engineering gap between laboratory yields and industrial throughput

Laboratory yields above 90% are genuinely impressive. They are also where the optimism should stop, because the barriers between a beaker and a bioreactor are physical, temporal, and stubborn.

The core problem is maintaining stable microbial communities at the high pulp densities that industrial economics demand. Keeping the microbes alive, active, and well-supplied with oxygen and nutrients under realistic loading conditions is a mass-transfer challenge that laboratory conditions rarely replicate.

Toxicity and throughput velocity

The metals themselves are the enemy. At industrial loadings around 100 grams per litre, heavy metal concentrations become toxic to the very organisms trying to extract them.

That toxicity threshold is the reason process intensification research matters. In April 2026, the NLR program advanced evolutionary engineering, deliberately breeding acid-loving microbes to tolerate the high lithium, cobalt, and nickel concentrations that scaling requires.

The NLR critical minerals research program identifies metal toxicity as a key limitation preventing widespread adoption of biomining biotechnology, a finding that directly frames why evolutionary engineering of acid-tolerant microbial strains has become the sector’s primary scaling pathway.

Speed cuts the other way, and here the picture is genuinely mixed. A July 2026 open-access article reported spent-medium bioleaching using Acidithiobacillus thiooxidans achieving 100% cobalt and 72% nickel recovery in just 2 hours at low pulp density.

Contrast that with fungal leaching, where Aspergillus niger can take 7 to 14 days to mobilise 70-90% of target metals from cathodes. Conventional hydrometallurgy delivers comparable results far faster.

Fungal leaching using species like Aspergillus niger operates through different organic acid production pathways than bacterial routes, and its slower kinetics, typically 7-14 days per cycle, reflect a fundamentally different metabolic mechanism rather than simply an inferior version of the bacterial approach.

Evolutionary engineering is the primary pathway through the toxicity bottleneck, but breeding tolerance takes time, and time is the resource this sector is short of.

Feedstock heterogeneity

The second barrier is that no two waste streams look alike. Cathode chemistries are shifting from NMC (nickel-manganese-cobalt) to LFP (lithium-iron-phosphate), and each change disrupts a biological process tuned for the previous input.

Geothermal brines, mine tailings, and black mass all carry variable, unpredictable compositions. That variability complicates process control and makes recovery predictability difficult, which is a serious operational risk when your extraction agent is a living organism sensitive to its environment.

The interpretation for your capital is direct. This timeline mismatch tells you biological processes will not scale fast enough to solve the structural supply deficits projected for this decade. Any position you take here demands a long-duration horizon, and your due diligence checklist should require solutions to these specific barriers, not just a headline recovery percentage.

Valuing ESG premiums against technology execution risk

Strip away the science and the investment question becomes a straight comparison: does biological extraction beat the alternatives already scaling? On pure throughput, the honest answer is no. The case rests elsewhere.

The environmental credentials are real. Bioleaching operates at ambient or moderately elevated temperatures of 30-40°C, requiring no fossil fuel combustion for heat, unlike conventional smelting, which is energy-intensive and produces significant CO2 and SO2 emissions.

That is where the premium financing narrative lives. As regulatory frameworks tighten, biologically based methods may access favourable financing or premium markets that reward low-emission processing.

The competing low-emission pathways, however, are further ahead:

• Hydrometallurgical recycling: The near-term default. Advanced leaching and solvent extraction achieve up to 85% lithium recovery and over 95% cobalt and nickel recovery, far faster than bio-routes, though with higher chemical usage and more waste.
• Direct lithium extraction (DLE): Selectively recovers lithium from brines with a smaller water and land footprint, and carries a much clearer near-term scale-up trajectory than biological brine extraction, which remains largely conceptual.
• Urban mining: Mechanical-chemical recycling is the mainstream route for secondary lithium, cobalt, and nickel through the 2020s, with mature solvent-extraction technology.

A hybrid competitor is also emerging. In late 2025, a study in Bioresource Technology evaluated microbial electro-extraction, where electroactive microbes reduce nickel, cobalt, and manganese in spent battery powder, potentially blending biological and electrochemical routes.

EV battery recycling sits at the intersection of these competing processing routes, with mechanical-chemical methods currently dominating commercial throughput while biological approaches compete on ESG credentials rather than cycle time.

There are unique risks to weigh, too. Intellectual property defensibility, patents on microbial strains and processes, is critical, and handling genetically modified organisms at scale raises permitting questions that established chemical plants never face.

Your evaluation of any asset here must therefore weight two things heavily: the strength of its IP moat, and its capacity to command an ESG premium. On raw throughput metrics, it will likely lose to conventional extraction.

Structuring long-duration exposure to biological extraction

The evidence points to one conclusion: biological extraction of battery metals is a highly promising but long-duration ESG play, not a near-term fix for mineral scarcity.

The technology is more likely to complement direct lithium extraction and advanced chemical processing than replace them, treating specific low-grade waste streams where the environmental benefits justify a slower process. History supports patience here, given how long commercial copper and gold bioleaching took to reach widespread adoption.

The single milestone to monitor is the shift from batch laboratory testing to continuous, industrial-scale pilot plants. That transition is where recovery rates meet reality, and where the winners will separate from the pitch decks.

When you next read a startup’s claim of 95% recovery, interrogate the pulp density, the feedstock consistency, and the throughput velocity behind it.

For investors exploring the broader biological extraction investment universe, our full explainer on microbial rare earth extraction covers how phytomining and microbial routes are being applied to rare earth elements, a parallel technology pathway with its own distinct commercialisation timeline and ESG premium narrative.

This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with financial professionals before making investment decisions.

Past performance does not guarantee future results. Financial projections are subject to market conditions and various risk factors. Forward-looking statements regarding technology development are speculative and subject to change based on market and company developments.